Neurotransmission defects and mental health: Focus on schizophrenia

Question 1

What is the state of diagnosis for schizophrenia?

Answer 1

There’s no diagnostic pathology

- its diagnosis is currently based on clusters of symptoms: positive and negative

Question 2

What is the relatability of schizophrenia with other psychiatric disorders?

Answer 2

> Similarly to other psychiatric disorders, patients display cognitive impairments
However, schizophrenia is characterised by psychotic episodes consisting of both positive and negative symptoms

Question 3

What are positive symptoms?

Answer 3

Additional features that are not ordinarily present.

Question 4

What are the positive symptoms in schizophrenia?

Answer 4

> Delusions
Hallucinations
Thought disorder (potentially perceived in the patient’s speech)

Question 5

What are negative symptoms?

Answer 5

Refers to a loss or reduction in normal function.

Question 6

What are the negative symptoms in schizophrenia?

Answer 6

> Alogia: reduced speech
Affective flattening: lack of emotional facial expression
Avolition: diminished ability to begin and sustain an activity
Anhedonia: inability to find pleasure in something previously enjoyable
Asociality: social withdrawal

Question 7

What the cognitive impairments in schizophrenia?

Answer 7

> Working memory
Spatial memory
Attention span
Executive functions

Question 8

What are the possible life courses of people following a diagnosis of schizophrenia?

Answer 8

> Group 1: one episode with no impairment
- 22% of patients

> Group 2: several episodes with minimal or no impairment
- 35%

> Group 3: Impairment after the first episode, with exacerbation and no return to normality
- 8%

> Group 4: Increasing impairment with each episode, and no return to normality
- 35%

Question 9

What are the environmental factors of schizophrenia?

Answer 9

> Obstetric complications (pregnancy and birth)
Exposure to infection or inflammation
Exposure to social stress (childhood trauma is common)
Drug use (cannabis)

Question 10

What are the genetic factors of schizophrenia?

Answer 10

> Heritability (highly heritable)
Rare variants of large effect (DISC1 gene, Nrxn1)
Common variants of small effect = ‘polygenic score’

Question 11

What is the degradation process of dopamine?

Answer 11

> MAO breaks it down presynaptically

> Cathecol-O-Methyl Transferase (COMT) breaks it down postsynaptically

Question 12

What is the role of presynaptic autoreceptors in dopaminergic neurotransmission?

Answer 12

They inhibit further dopamine release in the synaptic cleft.

Question 13

What are the 4 dopamine pathways of schizophrenia?

Answer 13

1. Mesolimbic pathway
   - from VTA to nucleus accumbens, striatum, amygdala, hippocampus
2. Mesocortical pathway
   - from VTA to PFC
3. Nigrostriatal pathway
   - from substantia nigra to striatum
4. Tuberoinfundibular pathway
   - from A8 dopamine nucleus, via hypothalamus, to pituitary gland (regulates HPA)

Question 14

What is the dopamine hypothesis of schizophrenia?

Answer 14

• Increase in dopaminergic neurotransmission in mesolimbic pathway
• Leads to abnormally high levels of dopamine in nucleus accumbens and striatum
• These underlie the positive symptoms

Question 15

What are the first key pieces of evidence that lead to the development of the dopamine hypothesis?

Answer 15

> 1950s: clinical observations

• chlorpromazine decreased the positive symptoms of schizophrenia
• other antipsychotic drugs developed

> 1963:
- Study shows antipsychotic drugs increased the amount of dopamine metabolites in the cerebral spinal fluid of patients

> 1980s to 2000s: PET scans on schizophrenia patients prescribed with amphetamines vs. healthy controls

• > Amphetamines increased dopamine neurotransmission which induced schizophrenia-like symptoms in healthy people
• > Amphetamines increased severity of patients’ symptoms

Question 16

What is positron emission tomography (PET)?

Answer 16

Non-invasive molecular imaging technique that allows characterisation and measurement of biologic processes in living systems

• by combining a biologically active molecule to a radionuclide tracer that emits photons detected by the scanner
• > visualisation of the three dimensional location of the radiolabelled molecule AND measure the amount of tracer to assess the function of a system or an organ

Question 17

What is the neuroimaging evidence for the dopamine hypothesis?

Answer 17

> Use of the radiolabelled analogue of dopamine 18 fluorodopa (18F-DOPA) to visualise dopamine synthesis and storage pathways

• proxy measure of dopamine synthesis capacity (rate of dopamine synthesis)
• > Increase of dopamine synthesis capacity in striatum correlates positively with the severity of positive symptoms

> More than 50 studies replicated these findings with different groups of schizophrenia patients around the world
=> robust evidence of dopamine dysfunction in schizophrenia

Question 18

What do the studies of antipsychotic drugs and their binding to the dopamine D2 receptors show?

Answer 18

> All antipsychotic drugs bind to the dopamine D2 receptors
However: clozapine has low affinity for D2 receptor yet its the most effective antipsychotic drug
- other antipsychotics bind to other NTs in the brain

=> Alteration of dopamine neurotransmission might not be the only factor in schizophrenia

> PET studies suggest that between 60% to 80% of D2 receptors must be blocked for maximum therapeutic effet

• > 80% threshold beyond which patients have extrapyramidal side effects or akathisia
• > Narrow drug therapeutic window

Question 19

What are extrapyramidal symptoms?

Answer 19

Reflect the action of antipsychotics on dopamine D2 receptors in other dopamine pathways
- such as nigrostriatal pathway, responsible for control of movement

Question 20

What is akathisia?

Answer 20

Extrapyramidal movement disorder consisting of difficulty in staying still, and a subjective sense of restlessness

Question 21

What is a drug therapeutic window?

Answer 21

Range of doses in which positive effects are seen without adverse side-effects

Question 22

Where can the excess of dopamine activity come from?

Answer 22

> Excess of dopamine production
Dopamine metabolising is not quick enough
Patient’s D2 receptors have been altered so they respond differently to dopamine binding - more sensitive to dopamine

Question 23

What does the stress-diathesis model suggest for the origin of the excess of dopamine activity?

Answer 23

An individual inherits several genes that encode for abnormal proteins
- leading to detective dopamine function in mesolimbic pathway -> positive symptoms consequently

Question 24

What is the evidence against the dopamine hypothesis of schizophrenia?

Answer 24

Significant proportion of treatment-resistant patients (not responding to anti-psychotics), seeing no improvement in their positive symptoms (30%)
-> dopamine hyperactivity is only one of the causes for the onset of schizophrenia

Question 25

What is the evidence showing that treatment-resistant patients do not have the same abnormalities of dopaminergic neurotransmission?

Answer 25

> Treatment-responders show

• high dopamine levels in striatum
• normal levels of Glu in frontal cortex

> Treatment-resistant patients

• do not have these high dopamine levels in striatum (undistinguishable from controls)
• show high levels of Glu in the frontal cortex

=> there are other NTs, such as Glu, that play a role in schizophrenia symptoms - not just dopamine
=> we need early identification of treatment-resistant patients to propose alternative drugs - glutamatergic drugs currently in development

Question 26

What are the 2 potential sub-types of schizophrenia?

Answer 26

1. Based on dopamine

2. Not dopamine-based

Question 27

Do antipsychotic drugs effectively treat the negative symptoms of schizophrenia?

Answer 27

Clinical evidence suggest otherwise.

Question 28

What are the NTs other than dopamine involved in schizophrenia?

Answer 28

> Treatment-resistant patients have elevated levels of Glu NTs in the frontal cortex
Atypical antipsychotics have a dual action at dopamine and serotonin receptors
Dopamine, Glu and GABA interact and regulate each other

Question 29

How is the glutamate-GABA-dopamine circuitry linked to the mesolimbic pathway?

Answer 29

> GABA interneurons in frontal cortex regulate cortical glutamatergic projections
Cortical projection neurons send Glu from frontal cortex to dopamine neurons in midbrain - mesolimbic pathway

Question 30

How do alterations of glutamate explain the positive symptoms of schizophrenia?

Answer 30

Glutamatergic cortical projection neurons become overactive due to reduction of GABA interneurons
-> activation of mesolimbic pathway at midbrain level -> high levels of dopamine in nucleus accumbens and striatum -> positive symptoms of schizophrenia

=> Inbalances in GABA and Glu may lead to dopamine imbalance

Question 31

What is the evidence for the alteration of glutamate causing the positive symptoms of schizophrenia?

Answer 31

Antagonists of N-methyl-D-aspartate (NMDA) receptors (e.g. ketamine) lead to excess glutamate
-> manifestation of positive symptoms in healthy individuals and exacerbates the positive symptoms of schizophrenia patients

Question 32

How do alterations of glutamate explain the negative symptoms of schizophrenia?

Answer 32

Deficiency of GABA cortical neurons

• > overactive glutamate cortical projection neurons -> hyper activation of GABA interneurons in midbrain -> block activity and firing of dopamine mesocortical projections, which become hypoactive and unable deliver adequate supplies of dopamine to frontal cortex
• > hypofrontality -> negative and cognitive symptoms

Question 33

What do the dopaminergic, glutamatergic and GABAergic connections show about neurotransmission and its altered activity?

Answer 33

Polysynaptic nature of neurotransmission
-> complex neuronal circuits and networks, which activity defines behavioural outcomes

> Defective activity will lead to behavioural disturbances driven by alterations of dopamine, GABA and glutamate neurotransmission